Gene: PIGV
Official Full Name: phosphatidylinositol glycan anchor biosynthesis class Vprovided by HGNC
Gene Summary: This gene encodes a mannosyltransferase enzyme involved in the biosynthesis of glycosylphosphatidylinositol (GPI). GPI is a complex glycolipid that functions as a membrane anchor for many proteins and plays a role in multiple cellular processes including protein sorting and signal transduction. The encoded protein is localized to the endoplasmic reticulum and transfers the second mannose to the GPI backbone. Mutations in this gene are associated with hyperphosphatasia cognitive disability syndrome. Alternatively spliced transcript variants have been observed for this gene. [provided by RefSeq, Feb 2011]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO15132 | PIGV Knockout cell line (HeLa) | Human | PIGV | 1:3~1:6 | Negative | Online Inquiry |
KO15133 | PIGV Knockout cell line (HCT 116) | Human | PIGV | 1:2~1:4 | Negative | Online Inquiry |
KO15134 | PIGV Knockout cell line (HEK293) | Human | PIGV | 1:3~1:6 | Negative | Online Inquiry |
KO15135 | PIGV Knockout cell line (A549) | Human | PIGV | 1:3~1:4 | Negative | Online Inquiry |
PIGV Gene Knockout Cell Lines represent a sophisticated tool in molecular biology, specifically engineered to study the PIGV gene's function through targeted genomic modification. PIGV encodes a key enzyme involved in glycosylphosphatidylinositol (GPI) anchor biosynthesis, a critical process for proper protein anchoring and function in eukaryotic cells. By employing CRISPR/Cas9 technology, our PIGV knockout cell lines allow for precise gene disruption, enabling researchers to investigate the downstream effects of PIGV deficiency on cellular physiology, signaling pathways, and associated diseases.
The primary function of these knockout cell lines lies in their ability to facilitate in-depth functional assays, pathway analyses, and drug screening efforts. Researchers can utilize these cell lines to model conditions associated with GPI-anchor biosynthesis disorders, thereby illuminating the molecular basis of diseases such as congenital disorders of glycosylation (CDG). This unique application contributes significantly to both fundamental and applied research across various fields, including genetics, cell biology, and therapeutic development.
Compared to traditional methods of gene disruption, such as random mutagenesis or chemical inhibitors, PIGV Gene Knockout Cell Lines provide consistent, reproducible results with greater specificity and efficiency. They enable the rapid generation of experimental models without the off-target effects commonly associated with earlier techniques. Moreover, their ease of use and versatility allows researchers to tailor experiments according to their specific hypotheses.
For researchers and clinicians focused on the pathophysiology of glycosylation disorders or those engaged in therapeutic approaches, our PIGV Gene Knockout Cell Lines offer invaluable insights into disease mechanisms and potential treatment avenues. As a company dedicated to innovation in the field of biological research, we pride ourselves on providing high-quality, scientifically validated products that empower the global research community. Our expertise and commitment to supporting groundbreaking research initiatives position us as a trusted partner in advancing scientific discovery.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.